Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Esperite (voorheen Cryo Save)  /  Esperite 2016

Ontvang nu dagelijks onze kooptips!

word abonnee

Esperite (voorheen Cryo Save)« Terug naar discussie overzicht

Esperite 2016

3.912 Posts
Pagina: «« 1 ... 90 91 92 93 94 ... 196 »» | Laatste | Omlaag ↓
  5. FRC 31 mei 2016 09:42
    On 30 May 2016, Esperite’s share price plummeted with approximately 36%. This enormous drop appears to have been triggered by an article in the 30 May edition of Dutch financial daily Het Financieële Dagblad (FD).

    The article does not provide any new information on the company, and appears to be solely based on the company’s financial statements that were published in April.

    As at the accounts date – 31 December 2015 – Esperite had a cash position amounting to €1.4 million and management acknowledged in the financial statements the free cash available to be insufficient to execute the Group’s new strategy. In accordance with the accounting rules, the company disclosed these uncertainties in the going concern statement, in which management gave a detailed explanation why it considered it appropriate to assume that the company is able to continue as a going concern. Also in accordance with the accounting rules, EY as reporting accountant in its audit opinion referred to these uncertainties and management’s disclosures – in a so-called “emphasis of matter” paragraph – and, as it considered the disclosures sufficient, issued an unqualified audit opinion. In fact, the auditor’s statement in the 2015 financial statements was the same as the one in the 2014 financial statements – which also included an emphasis of matter paragraph.

    The abovementioned disclosure in the financial statements in April has now – more than four weeks later – led to the FD claiming that the company is in financial distress, and (in a subsequent article in the FD’s 31 May edition) “fighting for its life” and that the accountant is warning investors about the company’s survival. In the opinion of the company, these suggestive claims are completely inappropriate and unbecoming from a renowned financial daily such as Het Financieele Dagblad. Whilst the company’s cash position needs to improve – a matter on which management has been transparent in the financial statements – the company’s existence is not at stake and management is confident about Esperite’s prospects.

    A second element in the FD’s 30 May publication that attracted much attention and also seems to have led to the enormous drop in the share price is the FD’s incorrect claim that EY has questioned the EUR 0.9m convertible loan note issued to the company’s CEO Mr. Amar in 2015. This related to the conversion of Mr. Amar’s current account – payment obligations that the company had towards him relating to remuneration and pre-paid investments and expenses – into a convertible loan note bearing 7% interest, which is equal to the interest on a convertible loan issued to a 3rd party during May 2015. The convertible loan was a key audit matter as it regards a related party transaction and related party transaction come with a risk of not being at arm’s length terms or in the ordinary course of business. Consequently, the convertible loan and its terms were carefully reviewed by EY.
    However, opposite to the FD’s claim, this review has not lead to EY questioning the convertible loan or qualifying it as (potentially) not at arm’s length or otherwise inappropriate. EY standard procedure regarding related party transactions did not lead to any concerns or remarks, and this transaction is not disputed by EY. Unfortunately, the FD did not contact the company prior to making its 30 May publication – had it done so, management would have no doubt been able to take away FD’s incorrect understanding about the convertible loan and EY’s findings and opinion regarding the same.

    The FD’s publications have been severely damaging to the company and its shareholders. Esperite will engage with the FD to discuss the matter, also with a view to better educate FD on the company so that inappropriate and ill-informed communications can be avoided in the future.

    About ESPERITE

    ESPERITE Group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and predictive medicine established in 2000.

    To learn more about the ESPERITE group, or to book an interview with CEO Frederic Amar: +31 575 548 998 – ir@esperite.com or visit the websites at www.esperite.com and www.genoma.com
  7. forum rang 4 Nel 31 mei 2016 09:45
    The article does not provide any new information on the company, and appears to be solely based on the company’s financial statements that were published in April.

    The FD’s publications have been severely damaging to the company and its shareholders. Esperite will engage with the FD to discuss the matter, also with a view to better educate FD on the company so that inappropriate and ill-informed communications can be avoided in the future.

    Fijne dag
  11. FRC 31 mei 2016 09:47
    Esperite weerspreekt financiële problemen

    AMSTERDAM (AFN) - Esperite, bekend van zijn stamcellenbank Cryo-Save, spreekt tegen dat het beursgenoteerde biotechbedrijf in financiële problemen verkeert. Berichtgeving van het Financieele Dagblad daarover is gebaseerd op oude informatie die bovendien verkeerd is geïnterpreteerd, zo stelde het bedrijf dinsdag in een verklaring.
    Na een artikel in het FD maandag kelderde het aandeel Esperite met ruim 36 procent op de beurs in Amsterdam. Dinsdag schreef de krant bovendien dat het bedrijf ,,vecht voor zijn leven'' en dat de accountant investeerders zou waarschuwen. Esperite noemt de berichtgeving ,,volstrekt ongepast" van een ,,gerenommeerde krant als het FD''.
    De waarschuwing van accountant EY in het jaarverslag zou slechts een formaliteit zijn. Ook zou onterecht zijn geschreven dat de accountant vraagtekens plaatste bij een converteerbare lening van negen ton voor Esperite-topman Frédéric Amar.
    Esperite zegt met het FD in gesprek te gaan om ,,ongepaste en slecht geïnformeerde publicaties" in de toekomst te voorkomen.
3.912 Posts
Pagina: «« 1 ... 90 91 92 93 94 ... 196 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 882,63 +1,42%
EUR/USD 1,0694 -0,33%
FTSE 100 8.139,83 +0,75%
Germany40^ 18.177,90 +0,09%
Gold spot 2.337,95 0,00%
NY-Nasdaq Composite 15.927,90 +2,03%

Stijgers

EBUSCO...
+9,33%
NX FIL...
+8,77%
ASMI
+7,26%
Alfen ...
+5,89%
PostNL
+3,82%

Dalers

SIGNIF...
-11,28%
Wereld...
-7,62%
AMG Cr...
-5,77%
IMCD
-4,90%
ABN AM...
-4,19%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!